{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34115762",
  "DateCompleted": {
    "Year": "2021",
    "Month": "06",
    "Day": "23"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "09",
    "Day": "20"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "06",
        "Day": "11"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "e0252687",
      "10.1371/journal.pone.0252687"
    ],
    "Journal": {
      "ISSN": "1932-6203",
      "JournalIssue": {
        "Volume": "16",
        "Issue": "6",
        "PubDate": {
          "Year": "2021"
        }
      },
      "Title": "PloS one",
      "ISOAbbreviation": "PLoS One"
    },
    "ArticleTitle": "Inactivation of SARS-CoV-2 virus in saliva using a guanidium based transport medium suitable for RT-PCR diagnostic assays.",
    "Pagination": {
      "StartPage": "e0252687",
      "MedlinePgn": "e0252687"
    },
    "Abstract": {
      "AbstractText": [
        "Upper respiratory samples used to test for SARS-CoV-2 virus may be infectious and present a hazard during transport and testing. A buffer with the ability to inactivate SARS-CoV-2 at the time of sample collection could simplify and expand testing for COVID-19 to non-conventional settings.",
        "We evaluated a guanidium thiocyanate-based buffer, eNAT\u2122 (Copan) as a possible transport and inactivation medium for downstream Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) testing to detect SARS-CoV-2. Inactivation of SARS-CoV-2 USA-WA1/2020 in eNAT and in diluted saliva was studied at different incubation times. The stability of viral RNA in eNAT was also evaluated for up to 7 days at room temperature (28\u00b0C), refrigerated conditions (4\u00b0C) and at 35\u00b0C.",
        "SARS-COV-2 virus spiked directly in eNAT could be inactivated at >5.6 log10 PFU/ml within a minute of incubation. When saliva was diluted 1:1 in eNAT, no cytopathic effect (CPE) on VeroE6 cells was observed, although SARS-CoV-2 RNA could be detected even after 30 min incubation and after two cell culture passages. A 1:2 (saliva:eNAT) dilution abrogated both CPE and detectable viral RNA after as little as 5 min incubation in eNAT. SARS-CoV-2 RNA from virus spiked at 5X the limit of detection remained positive up to 7 days of incubation in all tested conditions.",
        "eNAT and similar guanidinium thiocyanate-based media may be of value for transport, stabilization, and processing of clinical samples for RT-PCR based SARS-CoV-2 detection."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Center for Emerging Pathogens, Rutgers-New Jersey Medical School, Newark, New Jersey, United States of America."
          }
        ],
        "LastName": "Banik",
        "ForeName": "Sukalyani",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Center for Emerging Pathogens, Rutgers-New Jersey Medical School, Newark, New Jersey, United States of America."
          }
        ],
        "LastName": "Saibire",
        "ForeName": "Kaheerman",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Center for Emerging Pathogens, Rutgers-New Jersey Medical School, Newark, New Jersey, United States of America."
          }
        ],
        "LastName": "Suryavanshi",
        "ForeName": "Shraddha",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Cepheid, Sunnyvale, California, United States of America."
          }
        ],
        "LastName": "Johns",
        "ForeName": "Glenn",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Cepheid, Sunnyvale, California, United States of America."
          }
        ],
        "LastName": "Chakravorty",
        "ForeName": "Soumitesh",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Cepheid, Sunnyvale, California, United States of America."
          }
        ],
        "LastName": "Kwiatkowski",
        "ForeName": "Robert",
        "Initials": "R"
      },
      {
        "Identifier": [
          "0000-0001-5196-1571"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Center for Emerging Pathogens, Rutgers-New Jersey Medical School, Newark, New Jersey, United States of America."
          }
        ],
        "LastName": "Alland",
        "ForeName": "David",
        "Initials": "D"
      },
      {
        "Identifier": [
          "0000-0002-5217-6142"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Center for Emerging Pathogens, Rutgers-New Jersey Medical School, Newark, New Jersey, United States of America."
          }
        ],
        "LastName": "Banada",
        "ForeName": "Padmapriya P",
        "Initials": "PP"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R01 AI131617",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "PLoS One",
    "NlmUniqueID": "101285081",
    "ISSNLinking": "1932-6203"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Culture Media"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "RNA, Viral"
    },
    {
      "RegistryNumber": "JU58VJ6Y3B",
      "NameOfSubstance": "Guanidine"
    }
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "medRxiv. 2021 Jan 20;:",
      "PMID": "33501462"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "diagnosis",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "COVID-19 Nucleic Acid Testing"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Chlorocebus aethiops"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Culture Media"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Guanidine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Healthy Volunteers"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "RNA, Viral"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Reverse Transcriptase Polymerase Chain Reaction"
    },
    {
      "QualifierName": [
        "drug effects",
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "drug effects",
        "virology"
      ],
      "DescriptorName": "Saliva"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Specimen Handling"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vero Cells"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Virus Inactivation"
    }
  ],
  "CoiStatement": "R.K. G.J, and S.C. are employees of Cepheid Inc., which sells the Xpert Xpress SARS-CoV-2 test. D.A. receives research support and royalty payments from Cepheid. This does not alter our adherence to PLOS ONE policies on sharing data and materials."
}